TriangleNCT02684006 · OUTCOME
Number of Participants Who Discontinued Treatment Due to Toxicity
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- COUNT_OF_PARTICIPANTS
- Unit
- Participants
- Interval / dispersion
- Not reported
- Time frame
- From first dose of study treatment until discontinuation of study treatment (maximum up to approximately 89 months)
What was measured
Number of participants who discontinued treatment due to toxicity are reported in this outcome measure.
Analysis population: Safety analysis set included all participants who received at least one dose of study drug.
Groups in this outcome
Avelumab + Axitinib
Participants with aRCC received avelumab 10 mg/kg, IV at Q2W in a 6-week cycle plus axitinib 5 mg, orally BID. Each treatment cycle was 42 days.
Sunitinib
Participants with aRCC received sunitinib 50 mg orally, QD on a schedule of 4 weeks on treatment followed by 2 weeks off treatment (schedule 4/2 in 6-week cycles). Each treatment cycle was of 42 days.
| Group | Source count |
|---|---|
| Avelumab + Axitinib | 434 |
| Sunitinib | 439 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Avelumab + Axitinib | 136 | Not reported | 17.41 | Not reported | Not reported |
| Sunitinib | 65 | Not reported | 12.82 | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 17.41
- value
- 136
- group Id
- OG001
- lower Limit
- 12.82
- value
- 65
- denoms
- counts
- group Id
- OG000
- value
- 434
- group Id
- OG001
- value
- 439
- units
- Participants
- description
- Number of participants who discontinued treatment due to toxicity are reported in this outcome measure.
- groups
- description
- Participants with aRCC received avelumab 10 mg/kg, IV at Q2W in a 6-week cycle plus axitinib 5 mg, orally BID. Each treatment cycle was 42 days.
- id
- OG000
- title
- Avelumab + Axitinib
- description
- Participants with aRCC received sunitinib 50 mg orally, QD on a schedule of 4 weeks on treatment followed by 2 weeks off treatment (schedule 4/2 in 6-week cycles). Each treatment cycle was of 42 days.
- id
- OG001
- title
- Sunitinib
- param Type
- COUNT_OF_PARTICIPANTS
- population Description
- Safety analysis set included all participants who received at least one dose of study drug.
- reporting Status
- POSTED
- time Frame
- From first dose of study treatment until discontinuation of study treatment (maximum up to approximately 89 months)
- title
- Number of Participants Who Discontinued Treatment Due to Toxicity
- type
- SECONDARY
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice